SCHEMBL29933384

SCHEMBL29933384

Cc1cncc(C#Cc2cc(C(=O)N[C@H]3CCCC[C@@H]3O)ccc2C)c1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KIT P10721 6/20 0.49
DDR1 Q08345 5/20 0.49
CSF1R P07333 1/20 0.41
CNR1 P21554 4/20 0.41
RIPK2 O43353 1/20 0.39
ABL1 P00519 1/20 0.39
BCR P11274 1/20 0.39
TAS1R3 Q7RTX0 3/20 0.38
TAS1R1 Q7RTX1 3/20 0.38
TAS1R2 Q8TE23 3/20 0.38
FGFR1 P11362 3/20 0.38
KDR P35968 3/20 0.38
DDR2 Q16832 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
TACR2 P21452 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29933030 0.90 TAS1R3 (0.48) KITDDR1CSF1RCNR1ABL1
SCHEMBL29933192 0.89 KIT (0.47) KITDDR1CSF1RCNR1RIPK2
SCHEMBL29933176 0.88 KIT (0.47) KITDDR1CSF1RCNR1ABL1
SCHEMBL29933322 0.87 KIT (0.51) KITDDR1CSF1RCNR1ABL1
SCHEMBL29933073 0.85 KIT (0.47) KITDDR1CSF1RCNR1TACR2
SCHEMBL29933145 0.84 KIT (0.48) KITDDR1CSF1RCNR1ABL1
SCHEMBL29933159 0.82 LCK (0.54) KITDDR1CNR1ABL1BCR
SCHEMBL29932958 0.82 KIT (0.43) KITDDR1CSF1RCNR1TAS1R3
SCHEMBL29933061 0.81 KIT (0.42) KITDDR1CSF1RCNR1RIPK2
SCHEMBL29934104 0.78 TAS1R3 (0.44) KITDDR1CNR1TAS1R3TAS1R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12509424-B2 Compound and composition as PDGF receptor kinase inhibitor NIPPON SHINYAKU CO., LTD. (JP) 2025-12-30 US claimed
CN-119371371-A Compounds and compositions as PDGF receptor kinase inhibitors 日本新药株式会社 2025-01-28 CN claimed
CN-115315421-A Compounds and compositions as PDGF receptor kinase inhibitors 日本新药株式会社 2022-11-08 CN claimed
CN-119371371-A Compounds and compositions as PDGF receptor kinase inhibitors 日本新药株式会社 2025-01-28 CN disclosed
CN-115315421-B Compounds and compositions as PDGF receptor kinase inhibitors 日本新药株式会社 2024-12-03 CN disclosed
CN-115315421-A Compounds and compositions as PDGF receptor kinase inhibitors 日本新药株式会社 2022-11-08 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12509424-B2 Compound and composition as PDGF receptor kinase inhibitor PDGFRA, PDGFRB, PDGFA KIT 180/4885DDR1 1510/4885CSF1R 307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.